Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns.
Multi-parametric quantitative MRI of normal appearing white matter in multiple sclerosis, and the effect of disease activity on T2.
Immunology of Multiple Sclerosis.
Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.
Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder.
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
Pediatric Multiple Sclerosis.
Tract-specific and age-related variations of the spinal cord microstructure: a multi-parametric MRI study using diffusion tensor imaging (DTI) and inhomogeneous magnetization transfer (ihMT).
Gastro Effects Dog Oral MS Drug Tecfidera
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease.
Rebif approval application
New data reinforce efficacy of TECFIDERA® (dimethyl fumarate) in MS patients with high disease activity
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.
Differences in the burden of psychiatric comorbidity in MS vs the general population.
Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact.
10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.
Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis.
Glatiramer Acetate Protects Against Inflammatory Synaptopathy in Experimental Autoimmune Encephalomyelitis.
Pages
« first
‹ previous
…
33
34
35
36
37
38
39
40
41
…
next ›
last »